Monument Therapeutics
https://monumenttx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Monument Therapeutics
Improving Clinical Trials In Psychiatric Health Care
Kiri Granger, Monument Therapeutics’ chief scientific officer and executive director, and one of In Vivo’s 2022 Rising Leaders, hopes to take the company to the next level by rejecting the conventional one-size-fits-all approach to psychiatric clinical trials.
In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent
The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
UK Biotech Monument Uses Repurposed Drugs To Target CNS Conditions
Emerging Company Profile: Monument Therapeutics’ novel approach to CNS drug development focuses on repurposing existing drugs with the aid of digital biomarkers.
Company Information
- Industry
- Biotechnology
- Digital Health
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice